The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“In contrast to TLR ligands, which signal the presence of pathogens, the inflammasome may instead be important for signalling endogenous stres”
BackgroundApproaching the Asymptote? Evolution and Revolution in Immunology
Janeway, C. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,252
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
Geijtenbeek, T. B. H., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Middel, J., Cornelissen, I. L. M. H. A., Nottet, H. S. L. M., KewalRamani, V. N., Littman, D. R., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80694-7 · Cited by 2,447
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Hepatitis B Virus Immunopathogenesis
Chisari, F. V. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.29 · Cited by 1,609
(1988) · World Health Organization eBooks · Cited by 1,574
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542 · cited 1×
“Alum has recently been shown to activate NOD-like receptor family pyrin domain-containing protein 3 (NLRP3), and it has been suggested that this ability to stimulate the inflammasome is essential for the adjuvant activity of aluminium salt”
BackgroundDifferential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cited by
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Dendritic cell subsets in T cell programming: location dictates function
Eisenbarth, S. C. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0088-1 · Cited by 827
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
B cell memory: building two walls of protection against pathogens
Akkaya, M., Kwak, K., & Pierce, S. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0244-2 · Cited by 626
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
Self-citationInteractions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 448
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialLynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Role of nanoscale antigen organization on B-cell activation probed using DNA origami
Veneziano, R., Moyer, T. J., Stone, M. B., Wamhoff, E.-C., Read, B. J., Mukherjee, S., Shepherd, T. R., Das, J., Schief, W. R., Irvine, D. J., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0719-0 · Cited by 429
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Brune, K. D., Leneghan, D. B., Brian, I. J., Ishizuka, A. S., Bachmann, M. F., Draper, S. J., Biswas, S., & Howarth, M. (2016) · Scientific Reports · doi:10.1038/srep19234 · Cited by 412
Self-citationCurrent state and challenges in developing oral vaccines
Vela Ramirez, J. E., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 412
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
A melanin-mediated cancer immunotherapy patch
Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5692 · Cited by 381
Outer membrane vesicles as platform vaccine technology
van der Pol, L., Stork, M., & van der Ley, P. (2015) · Biotechnology Journal · doi:10.1002/biot.201400395 · Cited by 378
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Bacterial outer membrane vesicles as a platform for biomedical applications: An update
Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.031 · Cited by 370
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Hassett, K. J., Higgins, J., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 367
The role of nanotechnology in the treatment of viral infections
Singh, L., Kruger, H. G., Maguire, G. E. M., Govender, T., & Parboosing, R. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117713593 · Cited by 360
Self-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
Programmable polyproteams built using twin peptide superglues
Veggiani, G., Nakamura, T., Brenner, M. D., Gayet, R. V., Yan, J., Robinson, C. V., & Howarth, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519214113 · Cited by 348
High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles
Kuai, R., Li, D., Chen, Y. E., Moon, J. J., & Schwendeman, A. (2016) · ACS Nano · doi:10.1021/acsnano.5b07522 · Cited by 338
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Watson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 322
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Shape and size-dependent immune response to antigen-carrying nanoparticles
Kumar, S., Anselmo, A. C., Banerjee, A., Zakrewsky, M., & Mitragotri, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.069 · Cited by 307
Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M.-P., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 306
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
Tokatlian, T., Read, B. J., Jones, C. A., Kulp, D. W., Menis, S., Chang, J. Y. H., Steichen, J. M., Kumari, S., Allen, J. D., Dane, E. L., et al. (2019) · Science · doi:10.1126/science.aat9120 · Cited by 305
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis
Jain, A., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.016 · Cited by 304
Shi, G.-N., Zhang, C.-N., Xu, R., Niu, J.-F., Song, H.-J., Zhang, X.-Y., Wang, W.-W., Wang, Y.-M., Li, C., Wei, X.-Q., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.047 · Cited by 299
Gerner, M. Y., Torabi-Parizi, P., & Germain, R. N. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.024 · Cited by 299
Exosomes as divine messengers: are they the Hermes of modern molecular oncology?
Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., & Calin, G. A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.130 · Cited by 297
Lymph node targeting strategies to improve vaccination efficacy
Jiang, H., Wang, Q., & Sun, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.009 · Cited by 297
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Hong, S., Zhang, Z., Liu, H., Tian, M., Zhu, X., Zhang, Z., Wang, W., Zhou, X., Zhang, F., Ge, Q., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.012 · Cited by 296
A DNA Nanostructure Platform for Directed Assembly of Synthetic Vaccines
Liu, X., Xu, Y., Yu, T., Clifford, C., Liu, Y., Yan, H., & Chang, Y. (2012) · Nano Letters · doi:10.1021/nl301877k · Cited by 289
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Self-citationTailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
He, S., Li, J., Lyu, Y., Huang, J., & Pu, K. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c00659 · Cited by 282
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency
Hong, X., Zhong, X., Du, G., Hou, Y., Zhang, Y., Zhang, Z., Gong, T., Zhang, L., & Sun, X. (2020) · Science Advances · doi:10.1126/sciadv.aaz4462 · Cited by 276
Basu, P., Malvi, S. G., Joshi, S., Bhatla, N., Muwonge, R., Lucas, E., Verma, Y., Esmy, P. O., Poli, U. R. R., Shah, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00453-8 · Cited by 272
Protein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
“The physical properties of these particles are critical in their efficacy.(74) By mimicking a virus, virosomes can assist with antigen uptake into antigen presenting cells, cell activation and trafficking within the lymph system.”
BackgroundNext‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery
Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Sankaranarayanan, R., Prabhu, P. R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B. M., Esmy, P. O., Joshi, S., Poli, U. R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00414-3 · Cited by 242
Di, J., Du, Z., Wu, K., Jin, S., Wang, X., Li, T., & Xu, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03166-5 · Cited by 229
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine
Marsian, J., Fox, H., Bahar, M. W., Kotecha, A., Fry, E. E., Stuart, D. I., Macadam, A. J., Rowlands, D. J., & Lomonossoff, G. P. (2017) · Nature Communications · doi:10.1038/s41467-017-00090-w · Cited by 121
Harnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases
Prosperi, D., Colombo, M., Zanoni, I., & Granucci, F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.010 · Cited by 106
“Also, the natural ability of DCs to uptake NPs makes them an ideal tool to induce antigen specific tolerance [21].”
Datta, N. R., Krishnan, S., Speiser, D. E., Neufeld, E., Kuster, N., Bodis, S., & Hofmann, H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.016 · Cited by 92
Thoms, F., Jennings, G. T., Maudrich, M., Vogel, M., Haas, S., Zeltins, A., Hofmann-Lehmann, R., Riond, B., Grossmann, J., Hunziker, P., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.050 · Cited by 69
Self-citationToll-like receptor agonists: a patent review (2011 - 2013)
Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68
Zhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Messenger RNA‐based vaccines: progress, challenges, applications
Kramps, T., & Probst, J. (2013) · WIREs RNA · doi:10.1002/wrna.1189 · Cited by 50
Luo, L., Qin, T., Huang, Y., Zheng, S., Bo, R., Liu, Z., Xing, J., Hu, Y., Liu, J., & Wang, D. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1359861 · Cited by 47
Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset, F., Vazquez, T., & Bellier, B. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1046440 · Cited by 43
Bacteriophages as Solid Tumor Theragnostic Agents
Veeranarayanan, S., Azam, A. H., Kiga, K., Watanabe, S., & Cui, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010402 · Cited by 39
Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners
Thoms, F., Haas, S., Erhart, A., Nett, C. S., Rüfenacht, S., Graf, N., Strods, A., Patil, G., Leenadevi, T., Fontaine, M. C., et al. (2020) · Viruses · doi:10.3390/v12030288 · Cited by 37
“The VLP consists of the CuMV coat protein, without any viral genetic information, which serves as a carrier and induces, due to its particulate and repetitive structure, strong and sustained antibody responses, even against self molecules like the Fel d 1 protein in cats [38,39].”
BackgroundSelf-citationAyoub, S. S., Wood, E. G., Hassan, S.-U., & Bolton, C. (2011) · Inflammation Research · doi:10.1007/s00011-011-0352-3 · Cited by 19
Capella-Pujol, J., de Gast, M., Radić, L., Zon, I., Chumbe, A., Koekkoek, S., Olijhoek, W., Schinkel, J., van Gils, M. J., Sanders, R. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39690-0 · Cited by 12
Badten, A. J., & Torres, A. G. (2024) · Vaccines · doi:10.3390/vaccines12030313 · Cited by 8
Li, J., Xing, H., Meng, F., Liu, T., Hong, X., Han, X., Dong, Y., Li, M., Wang, Z., Zhang, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01277 · Cited by 2
Metadata
- Authors
- Bachmann, M. F., & Jennings, G. T.
- Venue
- Nature Reviews Immunology
- Published
- 2010-10-15
- Volume
- 10
- Issue
- 11
- Pages
- 787-796
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1991701295
- Cited by
- 2,106
- References
- 115
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.